CarMa connects Canadian biotech to global investors

CarMa Global Enterprise operates at the intersection of life sciences, biotechnology, and health-focused AI — connecting Canadian researchers with international capital to bring treatments to market faster.

Founded by Dr. Anirudh "A.K." Kumar, CarMa positions itself as a partner for teams with strong science who need help translating technical progress into investable stories and executable capital plans. The firm draws on a global network including ultra-high-net-worth individuals and private family offices in the Middle East and North Africa (MENA) to connect companies with investors who value both return and real-world impact.

"Our mandate is to help scientists move beyond a publish-or-perish mindset," Kumar said. "We empower them to take an idea, commercialize it, and bring that return on investment back to Canada."

CarMa supports companies across the capital journey from early fundraising through later-stage rounds, providing guidance on clinical and regulatory strategy. The firm's sector focus spans drug development and therapeutics, diagnostics, technology-enabled care including wearables, metabolics, and cell and stem-cell therapies.

The firm operates on four principles: science first, conviction over consensus, Eastern capital with global reach, and patient capital rooted in impact. Kumar emphasized that geography, privilege, or the absence of the right introduction should not limit health-care innovation.

"Success is ultimately measured by whether better treatments reach patients faster, more equitably, and with greater benefit to Canada's innovation economy," Kumar said. "We keep people and impact front and center. If the science is sound and it can scale globally, we'll back it with conviction and work to make access more equitable."

For a city with growing biotech ambitions, CarMa represents a model: connecting local science to capital flows that don't typically reach Canadian labs.